Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Outlook Therapeutics Inc
Nieuws
Outlook Therapeutics Inc
OTLK
NAS
: OTLK
| ISIN: US69012T2069
3/05/2024
8,600 USD
(+1,18%)
(+1,18%)
3/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
28 december 2023 ·
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
· Persbericht
28 december 2023 ·
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
· Persbericht
21 december 2023 ·
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
· Persbericht
14 december 2023 ·
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
· Persbericht
5 december 2023 ·
OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
· Persbericht
13 november 2023 ·
Outlook Investor Deadline Approaching
· Persbericht
13 november 2023 ·
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024
· Persbericht
11 november 2023 ·
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK
· Persbericht
11 november 2023 ·
ROSEN, AN INVESTOR RIGHTS LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
· Persbericht
9 november 2023 ·
Outlook Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Outlook Therapeutics, Inc.
· Persbericht
9 november 2023 ·
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
· Persbericht
4 november 2023 ·
Pomerantz Law Firm Announces the Filing of a Class Action Against Outlook Therapeutics, Inc. and Certain Officers - OTLK
· Persbericht
4 november 2023 ·
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
· Persbericht
26 oktober 2023 ·
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
· Persbericht
20 oktober 2023 ·
Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics?
· Persbericht
18 oktober 2023 ·
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
· Persbericht
9 oktober 2023 ·
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
· Persbericht
29 september 2023 ·
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
· Persbericht
31 augustus 2023 ·
Outlook Therapeutics, Inc. (OTLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm
· Persbericht
4 maart 2021 ·
Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe